Compare DOOO & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DOOO | APLS |
|---|---|---|
| Founded | 1937 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 2.7B |
| IPO Year | N/A | 2017 |
| Metric | DOOO | APLS |
|---|---|---|
| Price | $76.66 | $25.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $77.40 | $33.11 |
| AVG Volume (30 Days) | 183.2K | ★ 2.2M |
| Earning Date | 12-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.24 | ★ 0.36 |
| Revenue | ★ $5,730,422,869.00 | $1,016,397,000.00 |
| Revenue This Year | $6.06 | $29.00 |
| Revenue Next Year | $6.25 | N/A |
| P/E Ratio | $322.50 | ★ $70.45 |
| Revenue Growth | N/A | ★ 42.11 |
| 52 Week Low | $31.78 | $16.10 |
| 52 Week High | $78.07 | $35.71 |
| Indicator | DOOO | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 79.85 | 67.89 |
| Support Level | $68.61 | $23.54 |
| Resistance Level | $78.07 | $25.52 |
| Average True Range (ATR) | 2.33 | 0.92 |
| MACD | 1.20 | 0.61 |
| Stochastic Oscillator | 91.82 | 92.36 |
BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which has largely been divested (Manitou pontoon boats sale is set to close in the third quarter). At the end of fiscal 2025, the company sold its products through a network of more than 2,400 independent dealers and 140 distributors in around 130 countries.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.